Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

External validation of the P-Score in the prospective, pre-biopsy DEPROMP cohort: integrated mpMRI and PSMA PET/CT risk stratification for prostate cancer detection.

European journal of nuclear medicine and molecular imaging·2026
Same author

Habenula volume alterations in adults born very preterm.

Scientific reports·2026
Same author

Molecular imaging and immune cell adhesion via vascular adhesion protein-1 in idiopathic inflammatory myopathy: a case report.

EULAR rheumatology open·2026
Same author

[<sup>68</sup>Ga]Ga-DOTA-Siglec-9 PET/CT in newly diagnosed giant cell arteritis: an inflammation-specific, treatment-responsive molecular imaging biomarker.

RMD open·2026
Same author

Minor neuropsychological deficits and stage 2 of Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Quantifying the Renal Impact of [<sup>177</sup>Lu]Lu-PSMA-617: A Longitudinal Analysis of Real-World Data from the LUMEN Registry.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026

Related Experiment Video

Updated: May 12, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Radioimmunotherapy for peritoneal cancers.

Christof Seidl1, Markus Essler

  • 1Technische Universität München, Department of Nuclear Medicine, Ismaninger Strasse 22, 81675 Munich, Germany. christof.seidl@lrz.tum.de

Immunotherapy
|April 6, 2013
PubMed
Summary

Alpha-emitter radioimmunoconjugates show promise for treating peritoneal carcinomatosis, a widespread cancer complication. These targeted therapies may improve outcomes where other treatments have fallen short.

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Radiopharmaceutical Therapy

Background:

  • Peritoneal carcinomatosis is a common secondary cancer with a poor prognosis.
  • Standard treatment involves cytoreductive surgery and chemotherapy.
  • Targeted radionuclide therapy is being explored to improve therapeutic outcomes.

Purpose of the Study:

  • To evaluate the potential of alpha-emitter radioimmunoconjugates for treating peritoneal carcinomatosis.
  • To assess the efficacy of alpha-emitters in eradicating micrometastatic disease.

Main Methods:

  • Review of preclinical and clinical studies on radionuclide-targeted therapies.
  • Focus on alpha-emitters due to their high-energy particle emission for localized tumor cell eradication.
  • Analysis of experimental studies and a Phase I clinical trial in ovarian cancer.

More Related Videos

Near Infrared Photoimmunotherapy for Mouse Models of Pleural Dissemination
05:39

Near Infrared Photoimmunotherapy for Mouse Models of Pleural Dissemination

Published on: February 9, 2021

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Related Experiment Videos

Last Updated: May 12, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Near Infrared Photoimmunotherapy for Mouse Models of Pleural Dissemination
05:39

Near Infrared Photoimmunotherapy for Mouse Models of Pleural Dissemination

Published on: February 9, 2021

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Main Results:

  • Beta-emitters showed promise in early studies but failed to be confirmed in Phase III trials.
  • Alpha-particles demonstrate efficient eradication of small tumor nodules, ideal for micrometastatic disease.
  • Alpha-emitter radioimmunoconjugates have shown success in experimental models and a Phase I ovarian cancer study.

Conclusions:

  • Alpha-emitters represent a promising strategy for optimizing peritoneal carcinomatosis therapy.
  • Further clinical trials are needed to confirm efficacy and address availability challenges.
  • Targeted alpha-particle therapy could significantly improve treatment for peritoneal carcinomatosis.